Atezolizumab, also known as MPDL3280A, a high affinity-specific against PD-L1, is FDA approved for use in metastatic NSCLC after disease progression on platinum-containing chemotherapy. However, as it is a humanized antibody, it is immunogenic in mice. To overcome this issue, MPDL3280A-mIgG1-D265A was generated by recombinant DNA technology . Importantly, its constant region contains a point mutation D265A (a replacement of aspartic acid by alanine at position 265), resulting in the complete loss of cytolytic effector functions.
